Cowen & Co. analyst David Stone repeated his "buy" ratings onGenetics Institute Inc. and Xoma Corp. on Thursday, but only GIwas helped by his remarks.

Stone, who met Wednesday with GI officials, was impressedwith early results from the Cambridge, Mass.-based company'sclinical trials of macrophage colony stimulating factor (M-CSF) for cancer, according to his research assistant, JoyceLonergan. GI stock (NASDAQ:GENI) rose $2.75, closing at $32.75.

Stone's report may also have helped Chiron Corp. stock(NASDAQ:CHIR), which picked up $1.50 to close at $54. Chironannounced last month that it will merge with Cetus Corp.,which is also developing M-CSF. Cetus stock (NASDSAQ:CTUS)fell 13 cents, however, closing at $15.13.

Stone also repeated his buy on Xoma. Stone's view is thatXoma's second clinical trial strengthens the chances that itsE5 product for gram-negative sepsis will receive a positiverecommendation from a Food and Drug Administration advisorycommittee.

Despite Stone's favorable remarks, Xoma lost another $1,closing at $18.25. Xoma fell $2.75 on Wednesday afterShearson Lehman analyst Teena Lerner downgraded it.

(c) 1997 American Health Consultants. All rights reserved.